SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on September 11, 2003; DOI 10.1182/blood-2003-05-1406. This Article Full Text (PDF) All Versions of this Article: 2003-05-1406v1 103/2/428    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Faulkner, R. D Articles by Russell, N. H Search for Related Content PubMed PubMed Citation Articles by Faulkner, R. D Articles by Russell, N. H Social Bookmarking                   What's this? Submitted May 6, 2003 Accepted August 26, 2003 BEAM-Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity and survival in 65 patients Rowena D Faulkner*, Charles Craddock, Jennifer L Byrne, Prem Mahendra, Andrew P Haynes, Hugh G Prentice, Michael Potter, Antonio Pagliuca, Aloysius Ho, Stephen Devereux, Grant McQuaker, Ghulam Mufti, John Liu Yin, and Nigel H Russell Department of Haematology, City Hospital, Nottingham, United Kingdom Department of Haematology, University Hospital, Birmingham, United Kingdom Department of Haematology, Royal Free Hospital, London, United Kingdom Department of Haematology, Kings College Hospital, London, United Kingdom Department of Haematology, Glasgow Royal Infirmary, Glasgow, United Kingdom Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom * Corresponding author; email: rowena.bainton{at}nottingham.ac.uk. We report the outcomes of reduced-intensity allogeneic stem cell transplantation using BEAM-Campath conditioning (BCNU, etoposide, cytosine arabinoside, melphalan and Campath 10mg/day on days -5 to -1) in 6 UK Transplant Centres. Sixty five patients with lymphoproliferative diseases underwent sibling (n=57) or matched unrelated donor (n=8) transplantation. Sustained donor engraftment occurred in 60/62 patients (97%). 35/56 patients (63%) undergoing chimerism studies had full donor chimerism. 73% were in CR post-transplantation. At a median follow-up of 1.4 years (range 0.1-5.6 years), 37 remain alive and in CR. Acute GVHD occurred in 11/64 (17%), Grade I-II only. Estimated 1 year TRM was 8% for patients undergoing first transplantation but was significantly worse for those who had undergone previous autologous transplantation. Six patients relapsed (estimated 2 year relapse risk 20%). Histological diagnosis (MCL and high grade NHL) and age at transplantation (>46 years old) were significantly associated with higher relapse risk and worse EFS. Relapse did not occur in any patient who developed acute or chronic GVHD. This study demonstrates that reduced intensity allogeneic stem cell transplantation for lymphoproliferative diseases using a BEAM-Campath preparative regimen is associated with sustained donor engraftment, a high response rate, minimal toxicity and a low incidence of GVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. R. Mohan, M. J. Clemente, M. Afable, H. N. Cazzolli, N. Bejanyan, M. W. Wlodarski, A. E. Lichtin, and J. P. Maciejewski Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia Haematologica, October 1, 2009; 94(10): 1407 - 1414. [Abstract] [Full Text] [PDF] S. P. Robinson, A. Sureda, C. Canals, N. Russell, D. Caballero, A. Bacigalupo, A. Iriondo, G. Cook, A. Pettitt, G. Socie, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome Haematologica, February 1, 2009; 94(2): 230 - 238. [Abstract] [Full Text] [PDF] K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al. Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma J. Clin. Oncol., January 20, 2009; 27(3): 426 - 432. [Abstract] [Full Text] [PDF] A. Sureda, S. Robinson, C. Canals, A. M. Carella, M. A. Boogaerts, D. Caballero, A. E. Hunter, L. Kanz, S. Slavin, J. J. Cornelissen, et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., January 20, 2008; 26(3): 455 - 462. [Abstract] [Full Text] [PDF] M. L. Sorror, B. E. Storer, D. G. Maloney, B. M. Sandmaier, P. J. Martin, and R. Storb Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia Blood, January 1, 2008; 111(1): 446 - 452. [Abstract] [Full Text] [PDF] N. Schmitz, P. Dreger, B. Glass, and A. Sureda Allogeneic transplantation in lymphoma: current status Haematologica, November 1, 2007; 92(11): 1533 - 1548. [Abstract] [Full Text] [PDF] L. Farina and P. Corradini Current role of allogeneic stem cell transplantation in follicular lymphoma Haematologica, May 1, 2007; 92(5): 580 - 582. [Full Text] [PDF] S. J. Rodig, J. S. Abramson, G. S. Pinkus, S. P. Treon, D. M. Dorfman, H. Y. Dong, M. A. Shipp, and J. L. Kutok Heterogeneous CD52 Expression among Hematologic Neoplasms: Implications for the Use of Alemtuzumab (CAMPATH-1H) Clin. Cancer Res., December 1, 2006; 12(23): 7174 - 7179. [Abstract] [Full Text] [PDF] I. F. Khouri Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Hematology, January 1, 2006; 2006(1): 390 - 397. [Abstract] [Full Text] [PDF] N. L. Bartlett Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy Hematology, January 1, 2005; 2005(1): 245 - 251. [Abstract] [Full Text] [PDF] E. Morris, K. Thomson, C. Craddock, P. Mahendra, D. Milligan, G. Cook, G. M. Smith, A. Parker, S. Schey, R. Chopra, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma Blood, December 15, 2004; 104(13): 3865 - 3871. [Abstract] [Full Text] [PDF] M. B. Maris, B. M. Sandmaier, B. E. Storer, T. Chauncey, M. J. Stuart, R. T. Maziarz, E. Agura, A. A. Langston, M. Pulsipher, R. Storb, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma Blood, December 1, 2004; 104(12): 3535 - 3542. [Abstract] [Full Text] [PDF] J. N. Winter, R. D. Gascoyne, and K. Van Besien Low-Grade Lymphoma Hematology, January 1, 2004; 2004(1): 203 - 220. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020